Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine in patients with Non-Hodgkin Lymphoma.
The Republic of Ireland's Health Service Executive (HSE) has approved dose adjusted rituximab in combination with etoposide, prednisolone, doxorubicin, cyclophosphamide and vincristine (DA-R EPOCH) therapy for reimbursement as a treatment option for the treatment of patients with CD20 positive diffuse large B-cell Non Hodgkins Lymphoma (NHL).
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkins lymphoma (NHL).